{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Baker DL"],"funding":["NCI NIH HHS"],"pagination":["1313-23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2993160"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["363(14)"],"pubmed_abstract":["<h4>Background</h4>The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known.<h4>Methods</h4>We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology-based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological"],"journal":["The New England journal of medicine"],"pubmed_title":["Outcome after reduced chemotherapy for intermediate-risk neuroblastoma."],"pmcid":["PMC2993160"],"funding_grant_id":["U10 CA098543","UI0-CA98543","UI0-CA29139","U10 CA029139","UI0-CA98413","U10 CA017829","U10 CA098413"],"pubmed_authors":["Maris JM","John H","Douglas H","Bostrom B","Granger M","Lenarsky C","Kreissman S","Kuttesch J","Larsen E","Estrada J","Termuhlen A","Dickens D","Furman W","Reynolds CP","Weinblatt M","Seeger RC","Taylor J","Shimada H","Cairney A","Johnson MC","Grewal S","Kuerbitz S","Ozkaynak M","Shen V","Frantz C","Shamberger RC","Look AT","Barnette P","Feusner J","Ravindranath Y","Samson Y","Fallon R","Brecher M","Rodriguez-Galindo C","Drachtman R","Cohn SL","Walterhouse D","Boklan J","Children’s Oncology Group","Silva M","Yanofsky R","Bertolone S","Johnston J","Balis F","Ricafort R","Bernstein J","Becton D","McLean T","Yu L","Chatchawin A","Wittman B","Prasannan L","Arndt C","Christopher M","Cole C","Turner C","Kobrinsky N","Irving H","Main C","Bassem R","Lee A","Hetherington M","York T","Stein D","Thomas P","Halton J","Kiley V","Chang E","Gowda N","Tekautz T","Cherrick I","McMahon D","Kelly M","Katzenstein H","Stroud C","De Santes K","Pais R","Ferguson W","London WB","Appel B","Neglia J","Arceci R","Ammann R","McDonough C","Mitchell T","Felgenhauer J","Matthay KK","Broxson E","Gera R","Arlene R","Fu C","Chaffee S","Loew T","Bryant P","McCowage G","Greenwood M","Lee Y","Hanif I","Daghistani D","Ritchey A","Kupfer G","Portwine C","Kumar M","Castleberry RP","Kirkpatrick G","Roberts W","Lowe E","Schmidt M","Homans A","Matloub YJ","Weinstein H","Ashley D","Hand J","Daniel G","McNall-Knapp R","Isakoff M","Selsky C","Neely J","Luis C","Keuker C","Chauvenet A","Reddy A","Schmidt ML","Salvi S","Ducore J","Atkinson M","Lockhart S","Bedros A","Dome J","Perentesis J","Salman E","Crouse V","McManus M","Godder K","Bond M","Olson J","Kwon JH","Kanwar V","Grant R","Schorin M","Hackney L","Strother D","Kraveka J","Gold S","Finklestein J","Maloney K","Baker DL","Hayashi R","Buxton A","Joseph W","Schwartz C","Goldsby R","Winick N","Sandler A","Winter S","Michon B","Cohn S","Louie R","Smith A","Lobel J","Mascarenhas L","Stram D","Kretschmar C","Jasty R","Tannous R","Sandler E","Kamalakar P","Shad A","Desai SJ","Smith S","Marina N","Scher C","Mody R","Cameron T","Beck Popovic M","Bomgaars L","Megason G"],"additional_accession":[]},"is_claimable":false,"name":"Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.","description":"<h4>Background</h4>The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known.<h4>Methods</h4>We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology-based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Sep","modification":"2026-04-30T23:35:05.259Z","creation":"2019-03-27T00:36:58Z"},"accession":"S-EPMC2993160","cross_references":{"pubmed":["20879880"],"doi":["10.1056/NEJMoa1001527","10.1056/nejmoa1001527"]}}